摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(5aR,8aS,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5,8-dione

中文名称
——
中文别名
——
英文名称
(5aR,8aS,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5,8-dione
英文别名
(5aR,8aS,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-[2]benzofuro[5,6-f][1,3]benzodioxole-5,8-dione
(5aR,8aS,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5,8-dione化学式
CAS
——
化学式
C21H18O8
mdl
——
分子量
398.369
InChiKey
OJDRVIHXHQXFSH-JBBXEZCESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    29
  • 可旋转键数:
    3
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    101
  • 氢给体数:
    1
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    氘代碘甲烷(5aR,8aS,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5,8-dionepotassium carbonate 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 生成 (5aR,8aS,9R)-9-(3,5-dimethoxy-4-(trideuteromethoxy)phenyl)-5a,6,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxole-5,8-dione
    参考文献:
    名称:
    [EN] PICROPODOPHYLLIN DERIVATIVES FOR USE IN THERAPY
    [FR] DÉRIVÉS DE PICROPODOPHYLLINE POUR UTILISATION EN THÉRAPIE
    摘要:
    本发明涉及具有以下结构的新化合物(I): 其中R1为OH、H、D或-0-C(0)-C1C6烷基;R2为H或D;R3和R4分别为H或D;R5、R6和R7分别为H或D;除了化合物(5R,5aS,8aR,9R)-5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-呋喃[3',4':6,7]萘[2,3-d]-1,3-二氧杂环己-6(5aH)-酮(匹罗波多菲林)和(5R)-5,8,8a,9-四氢-5-(3,4,5-三甲氧基苯基)呋喃[3',4':6,7]萘[2,3-d]-1,3-二氧杂环己-6(5aH)-酮,[5R-(5.α.,5a.β.,8a.α.)](去羟匹罗波多菲林)。本发明还涉及包含所述化合物的药物组合物,以及所述化合物在治疗中的使用。
    公开号:
    WO2013132263A1
  • 作为产物:
    参考文献:
    名称:
    Immunosuppressive Cyclolignans
    摘要:
    The immunosuppressive activity of several lactonic, nonlactonic, and heterocycle-fused cyclolignans has been demonstrated for the first time by use of a T-cell-mediated immune response. Of the compounds tested, 4'-demethyldeoxypodophyllotoxin (8), beta-apopicropodophyllin (6), and the isoxazoline-fused cyclolignan 15 are the most potent with respect to their suppression of activated splenocytes.
    DOI:
    10.1021/jm960023h
点击查看最新优质反应信息

文献信息

  • Biomimetic synthesis of podophyllum lignans.
    作者:TETSUYA TAKEYA、YUKARI AKABANE、EIICHI KOTANI、SEISHO TOBINAGA
    DOI:10.1248/cpb.32.31
    日期:——
    (±)-lsopodophyllotoxone 6a and the related lactones 8a and 9a were synthesized by a biomimetic procedure from the ester 5a by oxidation with a CrO3-HBF4-MeCN reagent system in one step. 4'-Benzyl-isopodophyllotoxone 6b, 4'-benzyl-picropodophyllone 7b, and the γ-lactones 8b and 9b were also synthesized from the ester 5b by oxidation with the same reagent system.
    (±)-lsopodophyllotoxone 6a 和相关内酯 8a 和 9a 是通过生物模拟程序,以酯 5a 为原料,用 CrO3-HBF4-MeCN 试剂体系氧化一步合成的。4'-Benzyl-isopodophyllotoxone 6b、4'-benzyl-picropodophyllone 7b 以及 γ-内酯 8b 和 9b 也是用相同的试剂体系通过氧化从酯 5b 合成的。
  • [EN] PICROPODOPHYLLIN DERIVATIVES FOR USE IN THERAPY<br/>[FR] DÉRIVÉS DE PICROPODOPHYLLINE POUR UTILISATION EN THÉRAPIE
    申请人:AXELAR AB
    公开号:WO2013132263A1
    公开(公告)日:2013-09-12
    The present invention is directed to new compounds of formula (I) wherein R1 is OH, H, D or -0-C(0)-C1C6 alkyl; R2 is H or D; R3 and R4 is each and independently H or D; and R5, R6 and R7 is each and independently H or D; with the exception of the compounds (5R,5aS,8aR,9R)-5,8,8a,9-Tetrahydro-9-hydroxy-5- (3,4,5-trimethoxyphenyl)-furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one (picropodophyllin) and (5R)-5,8,8a,9-Tetrahydro-5-(3,4,5- trimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, [5R- (5. alpha., 5a. beta.,8a. alpha.)] (deoxypicropodophyllin). to a pharmaceutical composition comprising said compounds, and to the use of said compounds in therapy.
    本发明涉及具有以下结构的新化合物(I): 其中R1为OH、H、D或-0-C(0)-C1C6烷基;R2为H或D;R3和R4分别为H或D;R5、R6和R7分别为H或D;除了化合物(5R,5aS,8aR,9R)-5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-呋喃[3',4':6,7]萘[2,3-d]-1,3-二氧杂环己-6(5aH)-酮(匹罗波多菲林)和(5R)-5,8,8a,9-四氢-5-(3,4,5-三甲氧基苯基)呋喃[3',4':6,7]萘[2,3-d]-1,3-二氧杂环己-6(5aH)-酮,[5R-(5.α.,5a.β.,8a.α.)](去羟匹罗波多菲林)。本发明还涉及包含所述化合物的药物组合物,以及所述化合物在治疗中的使用。
  • Immunosuppressive Cyclolignans
    作者:Marina Gordaliza、Glynn T. Faircloth、M Angeles Castro、José M. Miguel del Corral、M Luisa López-Vázquez、Arturo San Feliciano
    DOI:10.1021/jm960023h
    日期:1996.1.1
    The immunosuppressive activity of several lactonic, nonlactonic, and heterocycle-fused cyclolignans has been demonstrated for the first time by use of a T-cell-mediated immune response. Of the compounds tested, 4'-demethyldeoxypodophyllotoxin (8), beta-apopicropodophyllin (6), and the isoxazoline-fused cyclolignan 15 are the most potent with respect to their suppression of activated splenocytes.
查看更多

同类化合物

鬼臼脂毒酮 鬼臼毒素-4-O-葡萄糖苷 鬼臼毒素 鬼臼毒素 苦鬼臼毒素 脱氧鬼臼毒素 磷酸依托泊甙 盾叶鬼臼素 澳白木脂素2 澳白木脂素1 替尼泊苷 托尼依托泊苷 去氧鬼臼毒素 克立米星C 他氟泊苷 丙氨酸,N-(羧基甲基)-(9CI) alpha-盾叶鬼臼素 alpha-依托泊苷 [(5R,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-8-氧代-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-5-基]丁酸酯 TOP-53二盐酸盐 NK-611盐酸盐 5,8,8a,9-四氢-9-羟基-5-(3,4,5-三甲氧基苯基)-(5R,5aR,8aR,9S)-呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5aH)-酮 4’-去甲鬼臼毒素 4’-去甲基表鬼臼毒素-Β-D-葡萄糖甙 4-{[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]氨基甲酰}苯基乙酸酯 4,6-O-苄叉-Β-D-葡萄糖甙鬼臼毒素 4'-去甲基表鬼臼毒素 4'-O-脱甲基-4-((4'-(1'-苯甲基哌啶基))氨基)-4-脱氧鬼臼毒 4 ’-去甲去氧鬼臼毒素 3-羟基-4H-吡喃-4-酮 3-氨基-N-[(5S,5aS,8aR,9R)-9-(4-羟基-3,5-二甲氧苯基)-8-羰基-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基]苯酰胺 2’-O-没食子酰基金丝桃甙 2(3H)-硫代酰苯,3-乙基二氢-3-(1-甲基乙基)-(9CI) 2'-氯依托泊苷 1-羟基-17-氧杂五环[6.6.5.0~2,7~.0~9,14~.0~15,19~]十九碳-2,4,6,9,11,13-六烯-16,18-二酮(non-preferredname) (8aR,9S)-9-[[(2R)-7,8-二羟基-2-(2-噻吩基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5S,5aS,8aR,9R)-5-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基-苯基)-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二氧戊环-8-酮 (5S,5aR,8aR,9R)-9-(4-羟基-3,5-二甲氧基-苯基)-5-(4-羟基苯基)硫烷基-5a,6,8a,9-四氢-5H-异苯并呋喃并[5,6-f][1,3]苯并二噁唑-8-酮 (5R,5aR,8aS,9S)-9-[(4-氨基苯基)氨基]-5-(4-羟基-3,5-二甲氧苯基)-5,8,8a,9-四氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-6(5aH)-酮盐酸(1:1) (5R,5aR,8aR,9R)-9-羟基-10-甲氧基-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(4-甲氧基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-9-[[(6R,7R,8R)-7,8-二羟基-2-(2-羟基苯基)-4,4a,6,7,8,8a-六氢吡喃并[5,6-d][1,3]二恶英-6-基]氧基]-5-(3,4,5-三甲氧基苯基)-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-F][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-8-羰基-9-(3,4,5-三甲氧苯基)-5,5a,6,8,8a,9-六氢呋喃并[3',4':6,7]萘并[2,3-d][1,3]二噁唑-5-基乙酸酯 (5R,5aR,8aR,9R)-5-(4-乙氧基-3,5-二甲氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R,5aR,8aR,9R)-5-(3,5-二甲氧基-4-丙氧基-苯基)-9-[(2R,3R,4S,5S,6R)-3,4,5-三羟基-6-(羟基甲基)四氢吡喃-2-基]氧基-5a,8,8a,9-四氢-5H-异苯并呋喃并[6,5-f][1,3]苯并二氧戊环-6-酮 (5R)-5,8,8ab,9-四氢-5b-(3,4,5-三甲氧基苯基)呋喃并[3',4':6,7]萘并[2,3-d]-1,3-二氧杂环戊烯-6(5abH),9-二酮 (5-氯吡啶-3-基)丙酸甲酯 (3aS,4S,9R,9aR)-4-[(4-氟苯基)氨基]-9-(4-羟基-3,5-二甲氧基苯基)-6,7-二甲氧基-3a,4,9,9a-四氢-3H-萘并[3,2-c]呋喃-1-酮 (3aR,4S,9R,9aR)-4,6,7-三羟基-9-(4-羟基-3,5-二甲氧苯基)-3a,4,9,9a-四氢萘并[2,3-c]呋喃-1(3H)-酮 (1R,3aS,4R,6aR)-4-(1,3-苯并二氧戊环-4-基)-1-(1,3-苯并二氧戊环-5-基)-3,3a,4,6a-四氢-1H-呋喃并[3,4-c]呋喃-6-酮